Roche Diagnostics sales beat market average:
This article was originally published in Clinica
Roche Diagnostics saw its sales rise 14% to SwF5.3 billion ($3.5 billion) in 1999, substantially faster than the global average, the Swiss company says. All four business units contributed to the strong sales. Operating profit rose 29% to SwF771 million. The company is bringing together some diagnostic and therapeutic products to provide integrated healthcare solutions, with packages available for conditions such as HIV, breast cancer and influenza.
You may also be interested in...
The EU has published an action plan that is intended to upgrade the bloc’s intellectual property framework while ensuring that goods such as medicines and vaccines are made as widely available as possible. The initiative is part of wide-ranging plans to support member states’ recovery from the pandemic crisis and help ensure the EU’s resilience to future health threats.
Execs On The Move: New CEO For Humacyte; Internal Moves At Trinity Biotech, CVRx, Oventus Medical And Cancer Genetics
Trinity Biotech's new CFO is an internal move; Humacyte replaces CEO; chief strategy officer role for former CVRx CFO; and more.
Teva received a “package of commercial side-deals” for agreeing to halt generic competition to Cephalon’s Provigil (modafinil) throughout the EU, which it “would not have achieved without committing to staying out of the market,” according to findings by the European Commission.